By Karen E. Roman Alladapt Immunotherapeutics, Inc., a clinical-stage company which develops therapeutics to address food allergies, announced data from its Phase 1/2 Harmony study which proves that ADP101, a multi-allergen oral immunotherapy (OIT), produced dose-dependent, clinically meaningful responses. The...

  By Karen E. Roman Promontory Therapeutics Inc., a clinical stage development company centered on small molecule immunotherapy in cancer, presented its latest results on its lead therapeutic candidate, PT-112. The results were exposed at the Society for Immunotherapy of...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) said it appointed Dr. James Bristol, an experienced biopharmaceutical executive with a background in research and drug discovery, to its Board of Directors. Before his retirement from Pfizer in 2007, Dr. Bristol...

By Daniella Parra Avertix Medical presented new data regarding its Guardian System, which can detect heart attacks in real-time and alert high-risk patients, at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the company said. Avertix said it showed a 150% increase...

By Daniella Parra Sparrow Pharmaceuticals said it initiated a Phase 2 ACSpire study for SPI-62, a potent HSD-1 inhibitor, targeting autonomous cortisol secretion (ACS). ACS results from excessive cortisol production due to benign adrenal tumors and can lead to severe...

By Daniella Parra Apollomics Inc. (Nasdaq: APLM) unveiled results from the KUNPENG clinical trial at ESMO 2023, showing vebreltinib’s potential as a treatment for cancers with MET alterations, they said. The Phase 2 trial by Apollomics’ partner, Avistone Biotechnology Ltd.,...

By Daniella Parra Zynex, Inc. (NASDAQ: ZYXI), a medical technology company specializing in non-invasive medical devices for pain management, rehabilitation and patient monitoring, has been recognized as the 23rd among the Top 100 Healthcare Technology Companies of 2023 by The...

By Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) said its SQore platform, which transforms intravenous biologic medicines, particularly monoclonal antibodies (mAbs), into subcutaneous formulations. The company said it reduced the viscosity of over 40 mAbs by up to...

Dr. David Tapolczay, Chief Executive Officer of Conduit Pharma By Exec Edge Editorial Staff Can you give me a brief description of what Conduit Pharma does? Conduit is a disease agnostic life science company providing an efficient model for compound...

    By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, recently announced it will issue and sell shares of preferred stock in a private placement. The transaction will provide up to $130 million to SAB...